TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06119087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation
Description: Mechanical insufflation (MI) is a chest physiotherapy exercise that will be performed using a type of mechanical insufflator-exsufflator (MI-E) known as the BiWaze Cough device. The device connects to a tube that can interface with a patient using either a facemask or mouthpiece.~Mechanical insufflation is a chest physiotherapy exercise that passively inflates the chest with positive pressure that is delivered in coordination with the patient's own inspiratory timing until maximal inflation capacity (MIC), determined by the patient or maximal chest rise on visual inspection. At MIC, the patient passively exhales, which completes one cycle. Prior literature has used a dose of 5 sets of 5 cycles once or twice daily. The maneuver is usually performed with assistance of a caregiver to hold the mask or mouthpiece in place.
Study: NCT04863898

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Drug-use stigma reduction intervention for HIV care and treatment clinic staff
Description: We will adapt the HP+ health facility HIV stigma-reduction intervention to focus on drug stigma in HIV CTCs. The intervention will address key stigma drivers, including fear, awareness of stigma, and stigmatizing attitudes and beliefs, through a participatory training approach that involves all levels of staff and is grounded in social cognitive theory principles. The approach seeks to reduce stigma through fostering empathy, interpersonal interactions (contact strategies) and building efficacy for stigma reduction through awareness, skills, and knowledge building. The intervention consists of five-2.5 hour participatory training sessions.
Study: NCT04831606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Offloading performed with a standard brace to the calf (Optima Diab, from Molliter).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced dressing
Description: Protect the wound with Advanced dressing
Study: NCT04771767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Trauma-Focused Cognitive Behavioural Therapy
Description: Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
Study: NCT05453708

Intervention type: OTHER
Intervention: Survey
Description: One 15-20-minute survey

Intervention type: OTHER
Intervention: Survey
Description: One 15-20-minute survey
Study: NCT02894827

Intervention type: BIOLOGICAL
Intervention: Blood sample

Intervention type: BIOLOGICAL
Intervention: Blood sample

Intervention type: OTHER
Intervention: Flow cytometry

Intervention type: OTHER
Intervention: Flow cytometry

Intervention type: OTHER
Intervention: western blot

Intervention type: OTHER
Intervention: western blot
Study: NCT05814068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihypertensive drug treatment
Description: Patients with hypertension will be treated for it by their physician
Study: NCT04832334

Intervention type: OTHER
Intervention: Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.
Description: Imagery ability was determined.

Intervention type: OTHER
Intervention: Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.
Description: Imagery ability was determined.

Intervention type: OTHER
Intervention: Berg Balance Scale, Functional Reach Test
Description: Balance level was determined.

Intervention type: OTHER
Intervention: Berg Balance Scale, Functional Reach Test
Description: Balance level was determined.

Intervention type: OTHER
Intervention: Timed Up and Go Test, Functional Independence Scale
Description: Functionality was evaluated.

Intervention type: OTHER
Intervention: Timed Up and Go Test, Functional Independence Scale
Description: Functionality was evaluated.
Study: NCT04622930

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered CBT for SAD
Description: 12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered CBT for SAD
Description: 12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study: NCT05606328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergency Department Delirium Screening and Detection Program (ED-DDP)
Description: Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses. No adaptations to the ED-DDP will occur between implementation sites and no data will be collected during implementation phases.
Study: NCT06021106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise application with virtual reality glasses
Description: In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3D background design was made by a software developer, a 360-degree printout was taken, and it was converted into a form that can be viewed with glasses. The exercise video is prepared as 20 minutes. Exercises were performed at patients' homes through home visits. A total of 24 sessions of exercises were performed three days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine treatment and care
Description: routine treatment and care
Study: NCT04831606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced dressing
Description: Protect the wound with Advanced dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Photobiomodulation
Description: 2 minutes irradiation of blue light performed with EmoLED device
Study: NCT05299086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)
Description: The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Drug (INCS = Fluticasone furoate nasal spray, Placebo = Normal saline nasal spray)
Description: The investigators want to compare the efficacy of intranasal corticosteroid between daily versus as needed use in children with perennial allergic rhinitis which had not been studied before.
Study: NCT04793100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmologic exam at inclusion and 12 months after CRVO
Description: As part of routine care : OCT-B (Optical coherence tomography-B), OCT-angiography (Optical coherence tomography and fluorescein angiography after pupillary dilatation (at inclusion only)~Added by the study :~* Assessment of best corrected visual acuity in letters read and validated using the ETDRS scale ;~* The shooting of a 10 second infrared movie by the Heidelberg Spectralis device centered on the head of the optic nerve (at inclusion only)~* A measurement of the eye tension with an air tonometer (at inclusion only)~* A blood pressure measurement (diastolic and systolic) and pulse measurement (at inclusion only)~* A color retinophotography (Optos) with autofluorescence images~* A color Doppler ultrasound of the optic nerve of both eyes will be performed, for patients treated at the Foundation A de Rothschild Hospital only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment standardization with aflibercept
Description: For patients requiring intravitreal injection
Study: NCT05756842

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey-based gel supplementation
Description: 70 g/day of a honey-based gel divided into 2 equal doses of 35 gr (in the morning and evening) for a total duration of 14 days
Study: NCT05736770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation and out of bed mobilization
Description: The Respiratory rehabilitation and out of bed mobilization group will perform following exercises: pre operative out of bed mobilization, active cycle breathing techniques, forced expiratory technique and volume based incentive spirometery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: The conventional exercise program group will perform :Flow based Incentive spirometery, Chest percussion if needed
Study: NCT06481930

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Cervical Lesions by Fluorescence Photoelectric Image
Description: The enrolled patients underwent fluorescence photoelectric cervical lesion image detection, followed by colposcopy and biopsy to obtain histopathological results. The results of fluorescence photoelectric image detection were compared with histopathological results, and at the same time compared with HPV and TCT results at the time of enrollment.
Study: NCT06128148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0322 50 mg qd
Description: JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0322 100 mg qd
Description: JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0322 200 mg qd
Description: JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0322 100 mg bid
Description: JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0322 150 mg bid
Description: JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYP0322 200 mg bid
Description: JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
Study: NCT05697965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: applying 1 gm of vancomycin powder intracapsularly during primary total knee and hip arthroplasty to prevent periprosthetic joint infection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee or total hip arthroplasty
Description: Primary total knee or total hip arthroplasty without using local vancomycin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee or total hip arthroplasty
Description: Primary total knee or total hip arthroplasty without using local vancomycin
Study: NCT04805645

Intervention type: OTHER
Intervention: No intervention (Retrospective Cohort Observational)
Description: No intervention as this study is a Retrospective Cohort Observational
Study: NCT05335135

Intervention type: OTHER
Intervention: TriageGO-MDW Clinical Decision Support
Description: TriageGO-MDW is non-device clinical decision support that provides patient-level clinical risk estimates based on clinical data derived from the electronic health record

Intervention type: OTHER
Intervention: Usual Care
Description: Clinical care without decision support provided by TriageGo-MDW
Study: NCT04813211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mobile artificial cervical vertebrae replacement
Description: 1. Position: The patient is in a supine position with the neck hyperextended, ensuring his/her neck and shoulders in a stable and neutral position before surgery and the cervical spine in a physiological curvature position.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebral body between them will be removed. A curette is used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. Intraoperatively, the midlines of the segment and the vertebra to be replaced should be mapped out. When decompression, the midline for decompression should not be deviated from the planned midlines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior cervical corpectomy and fusion
Description: 1. Position: The patient is in a supine position with the neck hyperextended.~2. Anesthesia: General anesthesia via oral tracheal intubation.~3. Surgical approach: Anterior cervical spine approach through the space between the visceral sheath and the vascular sheath.~4. Surgical method: Two intervertebral discs with adjacent lesions and part of the vertebrae between them will be removed. A curette will be used to carefully strike off the annulus fibrosus and cartilage on the surface of the adjacent upper and lower endplates. The removed vertebral bone will be trimmed into cancellous bone particles and filled in a cervical titanium cage with an appropriate size. The titanium cage will be implanted into the vertebral space, and fixed with adjacent vertebrae using anterior cervical titanium plates and screws.
Study: NCT05926791

Intervention type: OTHER
Intervention: Cosmetic product
Description: The educated group receives the cosmetic product SPF50+ according to the randomization list established at V1 and returns the products at V2
Study: NCT05233085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Participants will receive oral solution of AZD4041 as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Participants will receive oral solution of AZD4041 as stated in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4041
Description: Participants will receive oral solution of AZD4041 as stated in arm description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral solution of placebo as stated in arm description.
Study: NCT05012930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Foods - Meat
Description: Commercially available baby foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Foods - Dairy
Description: Commercially available baby foods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby Foods - Plant
Description: Commercially available baby foods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Foods from the home
Description: Caregiver will provide participant with usual foods from the home
Study: NCT06592443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP
Description: The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP + MI
Description: After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
Study: NCT06613451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Application
Description: Mobile Application Use on the Intravenous, Intramuscular and Subcutaneous Drug Administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Mobile Application Use on the Intravenous, Intramuscular and Subcutaneous Drug Administration
Study: NCT06615024

Intervention type: DIAGNOSTIC_TEST
Intervention: G6pd enzyme sickling test
Description: Measuring the enzyme level of G6PD and presence of Hbs

Intervention type: DIAGNOSTIC_TEST
Intervention: G6PD enzyme and sickling test
Description: Measuring enzyme level of G6PD and level of HbS

Intervention type: DIAGNOSTIC_TEST
Intervention: G6PD enzyme and HPLC
Description: Measuring G6PD enzyme level in neonates and measuring level of HbS
Study: NCT05879718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859
Description: PF-06823859 (intravenous infusion)
Study: NCT06242691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1200
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1200
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1200
Description: IV Infusion
Study: NCT06542432

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Disclosure of integrate risk score for coronary artery disease
Description: Participants will receive their integrated risk score for coronary disease along with an optional genetic counseling visit to discuss the results.
Study: NCT06672900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Commercially available supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (Sporanox)
Description: Commercially available supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-000184
Description: Study Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-000184
Description: Study Investigational Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-000184
Description: Study Investigational Product
Study: NCT06621329

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transnasal sphenopalatine ganglion block
Description: Transnasal sphenopalatine ganglion blocks will be performed using the Tx360 device. Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.
Study: NCT05621655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mid dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 60 µg of protein (20 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Recombinant Trivalent Subunit Rotavirus Vaccine
Description: 0.5 mL of vaccine containing a total of 90 µg of protein (30 µg of each P type) adjuvanted with 0.5 mg aluminum hydroxide.